Abstract
This review is aiming to discuss the prostate Specific Antigen [PSA] As Early Detection Approach for Prostate Cancer. A systemic search for the terms: Prostate Cancer, prevention, methods for early detection and screening using prostate specific antigen [PSA] was done up to 2018 in the period between the first of September to the 6th of October in different databases including Google Scholar, Science Direct and NCBI including PubMed, Studies has been rated as being high quality by an established evaluation process based on the DyunaMed criteria and its levels of evidence. Out of the five trials and studies, only the PLCO trial concluded to the fact that the prostate cancer screening using the prostate specific antigen shows no evidence in reducing the mortality from the disease after the follow-up period. This review concluded to the importance of using the PSA as a screening tool in reducing prostate mortality although more researches need to be done.